Filler Complications: What Has to Be Written Down Before One Happens?

Published October 1, 2026 · 7 minute read · General information, not legal advice. Your licensing regulators decide what applies to you.

A practice with a vascular occlusion protocol on the wall often has nothing written for anything else. That page exists because it is the one everybody talks about. The rest of the list gets handled by whoever is in the building that day: the infection at an injection site, the lump that shows up weeks after the visit, the nodule under the eye, the discoloration nobody photographed.

What follows is about the documents, not the medicine. Every clinical step on every page belongs to the clinician who holds accountability for the practice, written in their words and signed by them. Nothing here describes what any particular practice must do.

Filler complications are a list, not an event

The FDA's page on dermal fillers names the risk the field organizes around first: "The most concerning risk associated with the use of dermal fillers is unintentional injection into a blood vessel, leading to blocked blood vessels and poor blood supply to tissues." The same page lists reported complications including "necrosis (death of tissue), vision abnormalities including blindness, and stroke."

That is one entry on the page. It also lists swelling and bruising, infection at the injection site, allergic reaction, and "raised bumps in or under the skin (nodules or granulomas) that may need to be treated." Those are separate events with different timing and different readers.

There is a plain test for where a practice actually stands. Open the protocol section and count the pages that name one complication each. If the answer is one, the binder holds a vascular occlusion protocol and nothing behind it.

Dermal filler complications arrive on different clocks

This is the part that decides how the record is built rather than how the protocol reads. A 2023 review in the Journal of Plastic, Reconstructive and Aesthetic Surgery, retrieved through PubMed, describes the grouping used in the literature. Complications are classified "by the time of onset: immediate (within 24 h after injection), early (24 h to 4 weeks post-procedure), and late or delayed (>4 weeks after injection)" (DOI). That is a published classification, cited here as a source. It is not a rule that applies to any reader.

Read it as a filing problem and four things follow for the record.

• The onset date and time is a field of its own, separate from the treatment date. A record carrying one date cannot show the gap between them.
• The onset entry needs a place for who reported it and how, because a late presentation often arrives as a phone call rather than as a visit.
• The treatment record has to be findable by patient, by treatment area, by date and by injector, since a late presentation is identified by matching backwards through the file.
• The practice needs a written answer to who takes that call outside clinic hours and what they write down. It is an administrative decision, and it belongs to nobody until it is written.

What each page in the section has to name

The clinical content differs page to page. At record level the pages carry the same fields, and these are the ones that go missing when a page is downloaded rather than authored.

• A title naming one complication. Not the word "complications" as a single heading over a block of text.
• The author, the role, the signature and the date authored. The clinician who wrote the clinical content, identified on the page.
• Roles as job titles. Who does what, written as the role rather than as the name of whoever held it the week the page was drafted.
• The escalation and transfer path. Current numbers, with a date showing when they were last checked.
• Where the supplies for that page sit, and who checks them on what interval.
• The record to be completed afterward, named on the page, so it points at a form instead of at somebody's memory.
• A revision number and a review date. A page with neither cannot be matched to the drill that trained on it.

None of those fields is clinical. They are what a reader coming to the binder later checks before reading a word of the response steps.

Filler complications management and the record after the event are two documents

The protocol says what the practice intends to do. The record says what it did, and when, and who was there. Practices that build the first and skip the second reconstruct the event from memory weeks later, which is the worst available moment to be doing it.

What the record should show after a patient complication covers the second document, including how the incident record differs from the treatment note and which reporting channels sit outside the practice. What a vascular occlusion protocol should include covers the first for the one complication most practices have already written something for.

Treatment areas get named on the page, not their own binder

Under-eye, lip, nose and chin work carry different concerns, and the written response is not identical across them. That is not an argument for four binders. It is an argument for naming the areas a page applies to, and for carrying the area in writing on the treatment record rather than as a tick next to a printed list. A record that says "face" cannot be matched to anything weeks later.

Biostimulator complications sit in their own section

A practice offering more than one material needs the sections kept apart, because the timing and the written response differ between them. Filing biostimulator complications under the filler pages produces a binder that looks finished and answers a question nobody asked. A section divider costs nothing. Discovering the merge during an event costs the rest of the day.

The reporting channel belongs printed on the page

The FDA page names the channel in both its patient and its clinician sections: "You can file a voluntary report by phone at 1-800-FDA-1088 or online at MedWatch, the FDA Safety Information and Adverse Event Reporting program." Whether a particular event gets reported is a decision for the practice and the people carrying clinical accountability in it. The number and the program name belong on the page either way, because the moment someone needs them is not a moment for searching.

The Complication Protocol Bundle ships eighteen pages in this structure, one complication per page, with the clinical steps left blank for the practice's author to write and sign. The Emergency Documentation Set carries the records those pages point at. Neither supplies clinical content, because that belongs to whoever signs it.

Do this next

Open the protocol section and count the pages that name a single complication. Then pull the most recent treatment record in the file and check two fields: whether the treatment area is written rather than ticked, and whether there is anywhere to enter an onset date that is not the treatment date. Put the count and the two answers on one sheet and hand it to whoever holds clinical accountability. That sheet is the agenda for the next conversation about the binder, and it took three pages already in the file to produce.

Questions this guide answers

What should a filler complications protocol contain?

A separate page per complication rather than one page headed with the word. At record level each page carries the same fields: a title naming one complication, the name and role of the clinician who authored the clinical content with their signature and the date, the roles involved written as job titles, the escalation and transfer path with a date showing when the numbers were last checked, where the supplies for that page sit and who checks them, the record to be completed afterward named rather than assumed, and a revision number with a review date. The clinical steps between those fields belong to the author.

Is one protocol page enough for filler complications?

One page covers one complication. The FDA's page on dermal fillers lists several distinct reported events, and they differ in timing and in who takes the first call. A practice with a single page in the protocol section has written a protocol for one of them and nothing for the rest.

How long after a treatment can a complication appear?

Published reviews group them by onset rather than by severity alone. A 2023 review in the Journal of Plastic, Reconstructive and Aesthetic Surgery describes the grouping used in the literature as immediate (within 24 h after injection), early (24 h to 4 weeks post-procedure), and late or delayed (more than 4 weeks after injection). That is cited here as a source, not as a rule for any practice. What it means for the file is that a record carrying only the treatment date cannot show the gap, and that the onset date needs a field of its own.

Where do biostimulator complications go in the binder?

In their own section, not folded into the filler pages. A practice offering more than one material has more than one written response, and a binder that merges them reads as finished while answering the wrong question.

Who writes the clinical content on each page?

Whoever holds clinical accountability for the practice, which in most aesthetic settings is the supervising or medical director relationship. A page with no named author is the first thing a reader asks about, and a downloaded page filed without review has no author to name.

Related guides

• What Should a Vascular Occlusion Protocol Include?
• Your Emergency Protocol Is Not a Protocol Until Someone Has Drilled It
• What Goes in a Med Spa Emergency Binder